390 results on '"Robinson, Giles W"'
Search Results
52. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome
53. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
54. Preclinical studies of 5-fluoro-2′-deoxycytidine and tetrahydrouridine in pediatric brain tumors
55. Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
56. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor
57. LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG)
58. INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.
59. Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients
60. ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis
61. MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy
62. Atypical teratoid/rhabdoid tumor (ATRT) arising from the 3rd cranial nerve in infants: a clinical-radiological entity?
63. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
64. Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study
65. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
66. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group
67. [11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence
68. Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma
69. Rare cases of medulloblastoma with hypermutation
70. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
71. Medulloblastoma—translating discoveries from the bench to the bedside
72. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
73. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
74. Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
75. Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study
76. Rare cases of medulloblastoma with hypermutation.
77. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials
78. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
79. Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
80. Germline Mutations Predispose to Pediatric Medulloblastoma
81. Resolving medulloblastoma cellular architecture by single-cell genomics
82. Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial
83. Patient-Derived Orthotopic Xenografts and Cell Lines from Pediatric High-Grade Glioma Recapitulate the Heterogeneity of Histopathology, Molecular Signatures, and Drug Response
84. MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA
85. MBRS-24. FUNCTIONAL CHARACTERIZATION OF IKBKAP/ELP1 AS A NOVEL SHH MEDULLOBLASTOMA PREDISPOSITION GENE
86. PATH-09. SJMB12 CLINICAL TRIAL: DISCREPANCY BETWEEN LOCAL AND CENTRAL PATHOLOGY IN ASSESSING ANAPLASTIC MEDULLOBLASTOMA – REPORT FROM A SINGLE SITE EXPERIENCE
87. MBRS-20. CSF-DERIVED CIRCULATING TUMOR DNA AS A BIOMARKER FOR DISEASE PROGRESSION AND TUMOR EVOLUTION IN MEDULLOBLASTOMA
88. ETMR-06. DISSECTING THE MOLECULAR AND DEVELOPMENTAL BASIS OF PINEOBLASTOMA THROUGH GENOMICS
89. ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY
90. Impact of tumor location on medulloblastoma subtyping and treatment (Commentary on teo et al., page xxx)
91. Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial
92. Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study
93. Abstract B73: Second-generation molecular subgrouping of medulloblastoma: An international meta-analysis of Group 3 and Group 4 subtypes
94. The RACE to Develop New Targeted Therapies for Children With CNS Tumors
95. Genomics Paves the Way for Better Infant Medulloblastoma Therapy
96. Food Is Love: Partnering With Families to Provide Nourishment at the End of Life
97. Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed/refractory integrase interactor 1-negative tumors.
98. Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.
99. Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.
100. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.